Clinical trials · Texas
Solid Tumors (Phase 1) clinical trials in Texas
We’re tracking 158 recruiting solid tumors (phase 1) studies with a site in Texas — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Houston, TexasAges 1–30 - NCT05118789RecruitingPhase 1/Phase 2
Study drug for ROS1-positive lung or solid tumors
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Houston, TexasAges 12 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Houston, TexasAges 18 years+ - NCT05266612RecruitingPhase 1
Testing a cancer medicine for advanced solid tumors with HSV
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
Houston, TexasAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Houston, TexasAges 12 years+ - NCT05490472RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Dallas, TexasAges 18 years+ - NCT05536141RecruitingPhase 1
Study of AB521 for kidney cancer and other solid tumors
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
San Antonio, TexasAges 18 years+ - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT05868226RecruitingPhase 1
Early cancer drug study for adults with advanced tumors
This Phase 1 study tests early (first-in-program) cancer medicines in people whose cancer has not been adequately controlled. It helps researchers learn the safest dose and early signs of whether the treatment may work for different tumor types and treatments.
Houston, TexasAges 18 years+ - NCT05914116RecruitingPhase 1/Phase 2
Early study of DB-1311 with BNT324 for advanced solid tumors
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
Dallas, TexasAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Austin, TexasAges 18 years+ - NCT05941507RecruitingPhase 1/Phase 2
TROP2 antibody drug with anti–PD-1 for advanced solid tumors
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
Houston, TexasAges 18 years+ - NCT05985161RecruitingPhase 2
Selinexor for wilms tumor and other solid tumors
This trial tests a drug called selinexor for children and young adults with certain types of solid tumors (like Wilms tumor, rhabdoid tumors, MPNST, or others with specific genetic changes) that have come back or not responded to standard treatment. Participants take selinexor pills to see if it can shrink or control their cancer.
Fort Worth, TexasAges 1 year+ - NCT06136884RecruitingPhase 1
Study of AO-252 for advanced solid tumors with or without brain metastases
This trial tests an experimental oral pill (AO-252) that targets a protein called TACC3 in advanced solid tumors, including those that have spread to the brain. It is for people whose cancer has a specific genetic change (TP53 mutation) or who have prostate cancer, and who have already tried other treatments.
Dallas, TexasAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Houston, TexasAges 18 years+ - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Houston, TexasAges 12 years+ - NCT06598007RecruitingPhase 1/Phase 2
Studying CT3001 for advanced solid tumors
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
Houston, TexasAges 18 years+ - NCT06667141RecruitingPhase 1
Study of ACR-2316 for advanced solid tumors
This study tests a new targeted drug called ACR-2316 for people with specific advanced solid tumors that have already been treated but are no longer responding. It aims to see how well the drug works and how safe it is, while looking for a tumor that has certain markers (like a protein or genetic change) that may make the drug more effective.
Houston, TexasAges 18 years+ - NCT06721689RecruitingPhase 1/Phase 2
PEEL-224 with chemo for pediatric solid tumors
This trial tests a new drug called PEEL-224 combined with two chemotherapy medicines (vincristine and temozolomide) for children and young adults with certain solid tumors that have come back or not responded to treatment. It aims to see if this combination is safe and works against the cancer.
Houston, TexasAges 1–30 - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Houston, TexasAges 18 years+ - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
San Antonio, TexasAges 18 years+ - NCT06997029RecruitingPhase 1
Study of BMS-986500 for advanced solid tumors
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Fort Worth, TexasAges 18 years+ - NCT07086768RecruitingPhase 1
BSI-082 alone or with T-DXd for advanced solid tumors
This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.
San Antonio, TexasAges 18 years+ - NCT07317505RecruitingPhase 1
Study of JMT108 for Advanced Solid Tumors
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
Dallas, TexasAges 18 years+
Solid Tumors (Phase 1) trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting solid tumors (phase 1) studies listed above.
- The University of Texas MD Anderson Cancer Center · 13 studies
- NEXT Oncology · 6 studies
- Mary Crowley Cancer Research · 3 studies
- Research Site · 2 studies
- University of Texas Health Science Center at San Antonio · 2 studies
- University of Texas Southwestern Medical Center · 2 studies
- Baylor College of Medicine
- Clinical Site
What taking part in a solid tumors (phase 1) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there solid tumors (phase 1) clinical trials in Texas?
- Yes. We're currently tracking 158 recruiting solid tumors (phase 1) studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumors (phase 1) study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumors (phase 1) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumors (phase 1) studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.